Concomitant Use of rFVIIa and Emicizumab in People with Hemophilia A with Inhibitors: Current Perspectives and Emerging Clinical Evidence

Concomitant Use of rFVIIa and Emicizumab in People with Hemophilia A with Inhibitors: Current Perspectives and Emerging Clinical Evidence

Silvia Linari, Giancarlo Castaman Department of Oncology, Center for Bleeding Disorders and Coagulation, Careggi University Hospital, Florence, ItalyCorrespondence: Giancarlo CastamanDepartment of Oncology, Center for Bleeding Disorders and Coagulation, Careggi University Hospital, Largo G. Brambill...

Full description

Bibliographic Details
Main Authors: Linari S, Castaman G
Format: Article
Language:English
Published: Dove Medical Press 2020-05-01
Series:Therapeutics and Clinical Risk Management
Subjects:
hemophilia a
fviii inhibitors
emicizumab
by-passing agents
recombinant fviia
safety
Online Access:https://www.dovepress.com/concomitant-use-of-rfviia-and-emicizumab-in-people-with-hemophilia-a-w-peer-reviewed-article-TCRM

Internet

https://www.dovepress.com/concomitant-use-of-rfviia-and-emicizumab-in-people-with-hemophilia-a-w-peer-reviewed-article-TCRM

Similar Items